Mesoblast (MESO) Net Income Growth (1y) (2015 - 2023)

Mesoblast (MESO) Net Income Growth (1y) (2015 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 6.48%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -6.81%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 46.75%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 151.28%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -99.90%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -12.04%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 327.74%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 95.87%
10 Mesoblast 2.01 Bn 1.87 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2023 -2.41%
Mar 31, 2023 -12.68%
Dec 31, 2022 -5.62%
Sep 30, 2022 25.44%
Jun 30, 2022 2.69%
Mar 31, 2022 180.64%
Dec 31, 2021 200.69%
Sep 30, 2021 7.74%
Jun 30, 2021 25.07%
Mar 31, 2021 -98.50%
Dec 31, 2020 -15.46%
Sep 30, 2020 -347.56%
Jun 30, 2020 -67.26%
Mar 31, 2020 41.54%
Dec 31, 2019 -2.65%
Sep 30, 2019 71.87%
Jun 30, 2019 11.43%
Mar 31, 2019 -28.54%
Dec 31, 2018 -158.68%
Sep 30, 2018 -177.67%